文献速递淋巴瘤

滤泡性淋巴瘤与巨噬细胞:已批准及新型治疗的影响

Follicular lymphoma and macrophages: impact of approved and novel therapies.
PubMed 文献 · Blood Adv · 2021-01-01

滤泡性淋巴瘤(FL)细胞存活和增殖依赖巨噬细胞,高组织含量肿瘤相关巨噬细胞(TAMs)尤其M2表型与化疗患者不良预后相关。利妥昔单抗通过TAMs介导抗体依赖细胞毒性和吞噬作用挑战该范式,但临床研究结果不一,提示TAMs预后影响取决于治疗方案。本文综述放疗、化疗、抗CD20单抗、来那度胺及靶向药物对TAMs生物学、吞噬、极化和功能的影响。

要点

  • FL细胞体外增殖依赖巨噬细胞,高TAMs尤其M2表型与化疗不良预后相关。
  • 利妥昔单抗通过TAMs介导ADCC和ADCP,改变TAMs预后影响。
  • 不同方案下TAMs预后影响不一,需理解现有治疗对巨噬细胞功能的影响。

核心结论

  • TAMs对FL患者预后的影响可能取决于所给予的治疗,需更好理解现有治疗如何影响巨噬细胞功能。

研究设计与样本

  • 综述,总结已批准和新型FL治疗对TAMs生物学的影响,涵盖放疗、化疗、抗CD20单抗、来那度胺和靶向药物。

主要发现

  • 高组织含量TAMs尤其M2表型与化疗FL患者不良预后强相关。
  • 利妥昔单抗时代临床研究结果不一,TAMs预后影响因方案类型而异。
  • 新型CD47/SIRPα轴靶向药物正在开发,在FL中显示有前景的活性。

临床怎么用

  • 理解不同FL治疗对TAMs吞噬、极化和功能的影响,有助于制定更安全有效的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The survival and proliferation of follicular lymphoma (FL) cells are strongly dependent on macrophages, because their presence is necessary for the propagation of FL cells in vitro. To this regard, as also shown for the majority of solid tumors, a high tissue content of tumor-associated macrophages (TAMs), particularly if showing a protumoral phenotype (also called M2), is strongly associated with a poor outcome among patients with FL treated with chemotherapy. The introduction of rituximab, an anti-CD20 antibody that can be used by TAMs to facilitate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, has challenged this paradigm. In the rituximab era, clinical studies have yielded conflicting results in FL, showing variable outcomes based on the type of regimen used. This highlighted, for the first time, that the impact of TAMs on the prognosis of patients with FL may depend on the administered treatment, emphasizing the need to better understand how currently available therapies affect macrophage function in FL. We summarize the impact of approved and novel therapies for FL, including radiation therapy, chemotherapy, anti-CD20 monoclonal antibodies, lenalidomide, and targeted agents, on the biology of TAMs and describe their effects on macrophage phagocytosis, polarization, and function. Although novel agents targeting the CD47/SIRPα axis are being developed and show promising activity in FL, a deeper understanding of macrophage biology and their complex pathways will help to develop novel and safer therapeutic strategies for patients with this type of lymphoma.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gouni S, Marques-Piubelli ML, Strati P, et al. Follicular lymphoma and macrophages: impact of approved and novel therapies. Blood Adv. 2021. PMID: 34570196. doi:10.1182/bloodadvances.2021005722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。